CD274 and non-small cell lung carcinoma: At present, a range of immune checkpoint inhibitors, prominently represented by PD-1/PD-L1 inhibitors, have gained approval for treating various tumours, including non-small cell lung cancer, GC, liver cancer, and colorectal cancer [5].